Neutropenic sepsis is a potentially life-threatening condition when a patient with low neutrophil counts develops an infection that spirals out of control if not treated urgently and is usually seen in cancer patients on chemotherapy.
The recently developed immune checkpoint inhibitor has considerably improved the survival rate of patients with cancer. However, the problem with cancer immunotherapy is that only approximately 30%.
Interleukin-12, though a good cancer treatment, cause many side effects. Now, researchers developed new version that gets activated only after reaching the tumor.
E-Mail
Topics in Anti-Cancer Research covers new developments in the field of cancer diagnosis and drug therapy. Novel drugs as anticancer agents include natural and synthetic phenazirines and other anti-cancer compounds. The series also covers information on the current understanding of the pathology and molecular biology of specific neoplasms.
The diversity of research topics published in this book series give broad and valuable perspectives for cancer researchers, clinicians, cancer professionals aiming to develop novel anti-cancer targets and patents for the treatment of various cancers.
The topics covered in ninth volume are:
Recent Patents on Exosome-Derived Therapeutic Agents
Serrated Lesions of the Colon and Rectum: An Overview of Pathology and Emphasis on a New Classification